文献速递胸部肿瘤

重新审视用于癌症诊断的自身抗体特征组合

Rethinking Autoantibody Signature Panels for Cancer Diagnosis.
PubMed 文献 · J Thorac Oncol · 2017-01-23

研究假设基于癌症抗原自身抗体检测的诊断血液测试能区分良性结节与肺癌,构建了含25种血清自身抗体的蛋白微阵列,在125例NSCLC患者与125例匹配良性结节对照中测试。训练集逻辑回归c-index为0.691,验证集c-index为0.490,评分与最终诊断关系无统计学显著性(p=0.460)。结论认为当前抗原组合和检测格式下,基于癌症抗原自身抗体水平的分类算法对预测癌症存在无统计学显著价值。

要点

  • 训练集逻辑回归c-index为0.691,验证集模型c-index为0.490。
  • 自身抗体评分与最终诊断的关系无统计学显著性(p=0.460)。
  • 作者认为该方法存在固有的生物学局限性。

核心结论

  • 使用当前抗原组合和检测格式时,基于癌症抗原自身抗体水平的分类算法对预测癌症存在无统计学显著价值。
  • 作者认为该方法存在固有的生物学局限性。

研究设计与样本

  • 研究识别了25种与NSCLC相关的血清自身抗体并构建了含这些自身抗原的蛋白微阵列。
  • 用人血清测试微阵列,样本为125例NSCLC患者和125例匹配的良性结节对照。
  • 研究尝试开发能将两组分开的分类算法。

主要发现

  • 在训练数据集中,逻辑回归c-index统计量为0.691。
  • 在验证数据集中,由训练集模型生成的评分预测模型c-index为0.490。
  • 评分与结局(最终诊断)之间的关系无统计学显著性(p=0.460)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 作者认为该方法存在固有的生物学局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Most pulmonary nodules found on imaging studies are indeterminate, but because of the concern for lung cancer, all patients require further evaluation with resultant radiation risk, significant cost, and delays in diagnosis. We hypothesized that a diagnostic blood test based on detection of autoantibodies against cancer antigens would be able to distinguish a benign nodule from lung cancer. METHODS: We identified a panel of 25 serum autoantibodies associated with NSCLC and constructed a protein microarray containing the autoantigens. We tested the microarray with human sera (from 125 patients with NSCLC and 125 matched controls with a benign nodule) and attempted to develop a classification algorithm that would separate the two groups. RESULTS: In the training data set the logistic regression c-index statistic was 0.691; in the validation data set, the model predicting the score generated from the training set model had a c-index of 0.490. The relationship between the score and outcome (final diagnosis) was not statistically significant (p = 0.460). CONCLUSIONS: When the current panel of antigens and assay format was used, classification algorithms based on levels of autoantibodies to cancer antigens did not prove to have statistically significant value for predicting the presence of cancer. We suggest that there are inherent biological limitations to this approach.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Campa MJ, Gottlin EB, Herndon JE, et al. Rethinking Autoantibody Signature Panels for Cancer Diagnosis. J Thorac Oncol. 2017. PMID: 28126538. doi:10.1016/j.jtho.2017.01.017

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。